The Parkinson Progression Marker Initiative (PPMI)
Section snippets
PPMI study design
The PPMI cohort will comprise 400 recently diagnosed PD and 200 healthy subjects followed longitudinally and comprehensively for biomarker assessment using standardized data acquisition protocols at twenty-one clinical sites with expertise in subject recruitment and biomarker assessment. The PPMI steering committee directs the study through the clinical, imaging, genetics, bioanalytic, biorepository, statistics, and bioinformatics cores (Fig. 1). The steering committee includes PD biomarker
Discussion
While PPMI seeks to discover and validate PD biomarkers for all phases of PD, the most critical need is to identify one or more biomarkers to monitor disease progression. During the past two decades numerous studies have investigated potential disease modifying therapies (Parkinson Study Group, 1993, Parkinson Study Group, 2004, Parkinson Study Group, 2007, Olanow et al., 2006, Olanow et al., 2009, Vornov et al., 2006, Schapira et al., 2010). Much has been learned from these studies, but all
References (42)
Clinical core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans
Alzheimers Dement.
(2010)- et al.
Assessment of the progression of Parkinson's disease: a metabolic network approach
Lancet Neurol.
(2007) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Lancet Neurol.
(2010)- et al.
Progression of Parkinson's disease in the clinical phase: potential markers
Lancet Neurol.
(2009) TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial
Lancet Neurol.
(2006)Disease modification in Parkinson's disease
Lancet Neurol.
(2004)The Alzheimer's Disease Neuroimaging Initiative: perspectives of the Industry Scientific Advisory Board
Alzheimers Dement.
(2010)- et al.
The role of the core imaging laboratory in multicenter trials
Semin. Nucl. Med.
(2010) - et al.
Biomarker discovery in neurodegenerative diseases: a proteomic approach
Neurobiol. Dis.
(2009) Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects
Alzheimers Dement.
(2010)
Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies
Neurology
Invited Article: nervous system pathology in sporadic Parkinson disease
Neurology
Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations
Mov. Disord.
Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease
FASEB J.
Striatonigral degeneration: a clinico-pathological study
Brain
Early detection of Parkinson's disease: unmet needs
Neurodegener. Dis.
Lower body (vascular) parkinsonism
Arch. Neurol.
Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder
Neurology
The Parkinson's complex: parkinsonism is just the tip of the iceberg
Ann. Neurol.
Can we image premotor Parkinson disease?
Neurology
Biomarkers for Parkinson's disease: tools to assess Parkinson's disease onset and progression
Ann. Neurol.
Cited by (1241)
Impulse control behaviors and apathy commonly co-occur in de novo Parkinson's disease and predict the incidence of levodopa-induced dyskinesia
2024, Journal of Affective DisordersAn analysis of data leakage and generalizability in MRI based classification of Parkinson's Disease using explainable 2D Convolutional Neural Networks
2024, Digital Signal Processing: A Review JournalCognitive dysfunction in de novo Parkinson disease: Remitting vs. progressive cognitive impairment
2024, Parkinsonism and Related DisordersLearning conditional variational autoencoders with missing covariates
2024, Pattern RecognitionMicrostructural white matter changes underlying speech deficits in Parkinson's disease
2024, Brain and Language
- 1
Please see Appendix A for authors list with affiliations.